H�T�=o� �w~�Ǟ:@�]�!bh�!C?Ԥ�9pR�A���ݩX�_�����KcM ��'�b��X�q���8mT�)�j�h,n�9���~��"�+�s�+�u���~x���!f���'f�Ź�h04���oҽ����[�[�\�'��� 708 32 0000004962 00000 n
"%G5!R�G('f���@U �ӏR��cG'H���� �����}��LJH��ϟ��`���g%�֩�93�N~,i����z�j&ŧ��ɴ��OML�1{�*+CG��g�S���'c>����\�_���̲���`�r.F�1߼�����I��P������1��A����E��-� �#���� ���WZ`2�((��\l(z�B�*�!�ue�*6А���_\��W/����e�{�jM��DWהג��Z�r/�U!��r�ƹ��W��{S�Ɩ�M�e[7ض7�ul��sl���{5�5VYnj��t��!7��wl�^_װ��o�޳�V���ko��j��2�:_EC���ņ��F�Z�tu���mll���5�ؽu�_��֚ʫ������Z66�� 0000011814 00000 n Enrasentan is more selective for the endothelin A receptor but at the doses used in this study it would also have blocked endothelin B receptors on vascular smooth muscle and the endothelium. CONTRAINDICATIONS. Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%).To report suspected adverse reactions, contact Actelion at OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years. 0000010018 00000 n 0000000016 00000 n

Lindsay shares her experience from diagnosis to current treatment with OPSUMIT, and her PAH specialist, Dr J. Wesley McConnell, explains why he chose OPSUMIT for Lindsay.OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years. 0000000936 00000 n ,͝(��]{m��'�a�;zf��^J�6U]��$�6+K���ԩs����Z�vX����� �f;i.��?�8�ȃ|�pa��]�u]�,�.��qq'n��ˎ_|�,;�7�h!ˏ���j�a��ׯn9����?d���r��e�ȉŅ�yN"r��YZv�x��?�_�-��P4��'ߩA �zk�$&iN�#퐊�΄��5nH�:�l��X)� M�N=�p�N?���cM��k��-���T:���p�(B>�3N�uz'�#.���$}̨i�5_�+�Ō�ڲS����I<4�V��F 0000005510 00000 n

Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years. %%EOF

0000013812 00000 n Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years. 0000027048 00000 n 0000016225 00000 n Ambrisentan tablets are an endothelin receptor antagonist that is selective for the endothelin type-A (ETA) receptor.

0000002946 00000 n 0000008752 00000 n H��V�n�F}����F 739 0 obj<>stream If OPSUMIT is used during pregnancy, advise the patient of the potential risk to a fetus. INDICATION. Pregnancy: OPSUMIT may cause fetal harm when administered to a pregnant woman. %PDF-1.6 %���� 0000027758 00000 n Counsel men about potential effects on fertility.Most common adverse reactions (more frequent than placebo by ≥3%) were anemia (13% vs 3%), nasopharyngitis/pharyngitis (20% vs 13%), bronchitis (12% vs 6%), headache (14% vs 9%), influenza (6% vs 2%), and urinary tract infection (9% vs 6%).OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years. In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%).Pregnancy: OPSUMIT may cause fetal harm when administered to a pregnant woman. If OPSUMIT is used during pregnancy, advise the patient of the potential risk to a fetus.Due to the risk of embryo-fetal toxicity, OPSUMIT is available for females only through a restricted program called the OPSUMIT REMS Program.
0000002864 00000 n

0000027509 00000 n OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization for PAH. It has a molecular formula of C 22 H 22 N 2 O 4 and a molecular weight of 378.42. x��V}TS���� 4D�$ZE)*��F��q%��4��+:ڂ\���ĶJ ?����n��i�λZ�֕���h�"~N㴟;ggｹ �u��9�c�9�� @� b�A�Z�@��$2%U��K8Z2d�A��.˱�|��؛.S˜��iA���\�-z�LT�EN�&ӻ)�[�LͶI_����u�M����X��͝�@4s�p!�G�o� ��J\j�Z!l��T�J�#�f*#�B')!/G ���?.l��j�BQ��L׼�EM�ݙ� ��k �{�)��L��^W�0���i���tW�ƕFc�b��6}�����EExĂE�X �q��FEǰ��82D*��x���X?